Tus%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd

## TUSQ ### Overview TUSQ is a combination medication containing **tuberculosis (TB) medications**. It is used for the treatment of **tuberculosis**. ### Primary Indications * Treatment of **active tuberculosis** (pulmonary and extrapulmonary). * Treatment of **latent tuberculosis infection (LTBI)**, typically as part of a multi-drug regimen. ### Adult Dosing Dosing varies significantly based on the specific formulation and the phase of treatment (intensive or continuation). It is crucial to refer to the current treatment guidelines (e.g., CDC, WHO) for precise dosing. A common adult dosing regimen for the intensive phase of active TB treatment may involve: * **Isoniazid:** 5 mg/kg/day (max 300 mg/day) * **Rifampin:** 10 mg/kg/day (max 600 mg/day) * **Pyrazinamide:** 20-25 mg/kg/day (max 2000 mg/day) * **Ethambutol:** 15 mg/kg/day (max 2.5 g/day) The continuation phase typically involves fewer drugs and may be dosed differently. **Specific doses should be determined by a healthcare provider based on patient weight, renal/hepatic function, and treatment guidelines.** ### Pediatric Dosing Pediatric dosing is weight-based and mirrors adult drug indications. Specific doses for each component of TUSQ must be calculated by a healthcare provider experienced in pediatric TB treatment. * **Isoniazid:** 10 mg/kg/day (max 300 mg/day) * **Rifampin:** 15 mg/kg/day (max 600 mg/day) * **Pyrazinamide:** 20-30 mg/kg/day (max 2000 mg/day) * **Ethambutol:** 20 mg/kg/day (max 1.6 g/day) **Dosages are approximate and must be confirmed by a qualified clinician.** ### Dose Adjustments * **Renal Impairment:** * Isoniazid: No dose adjustment typically needed unless severe. * Rifampin: No dose adjustment typically needed. * Pyrazinamide: Reduce dose or extend interval in severe renal impairment. * Ethambutol: Dose reduction is necessary in renal impairment (creatinine clearance < 30 mL/min). * **Hepatic Impairment:** Caution is advised. Rifampin, isoniazid, and pyrazinamide can be hepatotoxic. Discontinue if liver enzymes become significantly elevated. ### Contraindications * Known hypersensitivity to any component of the medication. * Severe active liver disease. * History of isoniazid-induced hepatitis. * Optic neuritis (for Ethambutol). ### Adverse Effects * **Hepatotoxicity:** Most serious adverse effect, particularly with isoniazid, rifampin, and pyrazinamide. Monitor liver function tests regularly. * **Peripheral Neuropathy:** Associated with isoniazid; risk increased in malnutrition, alcoholism, diabetes, and pregnancy. Pyridoxine (vitamin B6) may be prescribed prophylactically. * **Gastrointestinal Upset:** Nausea, vomiting, abdominal pain. * **Ocular Toxicity:** Blurred vision, color blindness, decreased visual acuity (Ethambutol). * **Hematologic Abnormalities:** Thrombocytopenia, hemolytic anemia (Rifampin). * **Urine and Body Fluid Discoloration:** Reddish-orange discoloration of urine, tears, sweat, and saliva (Rifampin). * **Hypersensitivity Reactions:** Rash, fever. ### Key Drug Interactions * **CYP450 Interactions:** Rifampin is a potent inducer of CYP450 enzymes, significantly affecting the metabolism of numerous drugs (e.g., oral contraceptives, anticoagulants, antiretrovirals, antifungals, corticosteroids). * **Antacids:** May decrease absorption of isoniazid and rifampin. * **Alcohol:** Increased risk of hepatotoxicity with isoniazid. * **Antiretrovirals:** Complex interactions; specific guidance is needed. ### Monitoring * **Liver Function Tests (LFTs):** Baseline and periodic monitoring (e.g., monthly) during treatment. * **Renal Function Tests:** Baseline and periodic monitoring, especially in patients with known renal disease or when dose adjustments are considered. * **Visual Acuity and Color Vision:** Baseline and periodic monitoring for Ethambutol. * **Complete Blood Count (CBC):** Consider periodically, especially with rifampin. * **Patient Symptoms:** Monitor for signs of hepatotoxicity (jaundice, fatigue, anorexia), peripheral neuropathy (numbness, tingling), and visual disturbances. ### Clinical Pearls * TUSQ is typically used as part of a **multi-drug regimen** to prevent the development of drug resistance. * **Adherence is critical** for successful treatment and prevention of resistance. Directly Observed Therapy (DOT) may be beneficial. * **Rifampin can stain contact lenses permanently.** * **Pyridoxine (Vitamin B6) supplementation** is often recommended with isoniazid to prevent peripheral neuropathy. * **Timing of administration:** Rifampin should be taken on an empty stomach for maximal absorption, but may be taken with food if GI upset occurs. Isoniazid can be taken with or without food. *** **Disclaimer:** This information is intended for educational purposes only and does not constitute medical advice. Always consult the most current prescribing information and relevant clinical guidelines or a qualified healthcare professional before making any decisions about drug use or treatment.